Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ABECMA safely and effectively. See full prescribing information for ABECMA. ABECMA® (idecabtagene vicleucel), suspension for intravenous infusion Initial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-other
ABECMA is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
- generic_name
- idecabtagene vicleucel
- product_names
- idecabtagene vicleucel
- ndc
- 59572-515, 59572-515-01, 59572-515-02, 59572-515-03
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en